junct medication to artesunate. The two arms of treatment in all studies showed similar results for all haematological, biochemical and urine analysis results. In all studies only adverse events recorded during CRDS treatment arm was an increase in APTT. This adverse effect is well documented with CRDS and can be easily monitored with the subsequent adjustment of dosing.
There is an indication of the positive effect of CRDS on cytoadherence as recorded in phase A where a slight increase in parasitaemia has been observed after CRDS treatment without subjects presenting with malaria symptoms. In phases B, IIB and C CRDS facilitates clearance of parasite and fever clearance time (e. g. severity of disease). In addition, CRDS showed no recrudescence in patients treated with chloroquine in phase B. CRDS seems beneficial in cerebral malaria in patients where there is no organ damage present (renal failure and pulmonary oedema).
In conclusion CRDS was well tolerated in all studies. CRDS seems to augment disease process along the line of the results obtained from pre-clinical studies. It seems that the group of patients, which will benefit most are sever/ cerebral cases with no additional clinical complications such as renal failure and pulmonary oedema. These complications are rare in children. This group represents the majority of deaths recorded in Africa.
